Cushing's syndrome J Lancet, May, vol.13367, issue.9522, pp.1605-1622, 2006. ,
Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent ,
DOI : 10.1210/jc.2010-1942
Multisystem Morbidity and Mortality in Cushing's Syndrome: A Cohort Study, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.6 ,
DOI : 10.1210/jc.2012-3582
MANAGEMENT OF ENDOCRINE DISEASE: The burden of Cushing's disease: clinical and health-related quality of life aspects, European Journal of Endocrinology, vol.167, issue.3, pp.311-337, 2012. ,
DOI : 10.1530/EJE-11-1095
Medical therapy of Cushing's disease Pituitary, pp.77-82, 2002. ,
progrès récents Annales d'Endocrinologie, pp.107-110, 2012. ,
Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole, European Journal of Endocrinology, vol.172, issue.4, pp.473-81 ,
DOI : 10.1530/EJE-14-0913
Screening and diagnosis of Cushing's syndrome ,Endocrinol Metab Clin North Am, pp.385-402, 2005. ,
Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study, Journal of Clinical Endocrinology & Metabolism, vol.86, issue.1 ,
DOI : 10.1210/jc.86.1.117
Diagnosis and Complications of Cushing???s Syndrome: A Consensus Statement, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.12 ,
DOI : 10.1210/jc.2003-030871
Determination of urinary free cortisol by HPLC, Clin Chem, vol.43, issue.8, pp.1386-91, 1997. ,
NEWER DIAGNOSTIC TECHNIQUES AND PROBLEMS IN CUSHING'S DISEASE, Endocrinology and Metabolism Clinics of North America, vol.28, issue.1, pp.191-210, 1999. ,
DOI : 10.1016/S0889-8529(05)70063-3
The Diagnosis of Cushing's Syndrome: An Endocrine SocietyClinical Practice Guideline 15. Casonato A ,Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome, Blood Coagul Fibrinolysis, vol.10, issue.3, pp.145-51, 1999. ,
Morbidity and mortality in Cushing's disease: an epidemiological approach, Clinical Endocrinology, vol.97, issue.4 ,
DOI : 10.1016/0002-9343(52)90027-2
Mortality in Cushing's syndrome: data from 386 patients from a single tertiary referral center, European Journal of Endocrinology, vol.169, issue.5, pp.621-628, 2013. ,
DOI : 10.1530/EJE-13-0320
Predictors of Mortality and Long-term Outcomes in Treated Cushing's Disease: A Study of 346 Patients, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.3, 2013. ,
DOI : 10.1210/jc.2012-2893
Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up, European Journal of Endocrinology, vol.169, issue.5, pp.715-738, 2013. ,
DOI : 10.1530/EJE-13-0569
Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study, Journal of Clinical Endocrinology & Metabolism, vol.86, issue.1 ,
DOI : 10.1210/jc.86.1.117
Endothelial Dysfunction Aassociated with Hypercortisolism is Reversible in Cushing???s Syndrome, Endocrine Journal, vol.57, issue.3, pp.245-52, 2009. ,
DOI : 10.1507/endocrj.K09E-260
Cortisolemic Indices Predict Severe Infections in Cushing Syndrome Due to Ectopic Production of Adrenocorticotropin, Journal of Clinical Endocrinology & Metabolism, vol.85, issue.1, pp.42-49, 2000. ,
DOI : 10.1210/jc.85.1.42
Successful Treatment of Cushing???s Syndrome with the Glucocorticoid Antagonist RU 486*, The Journal of Clinical Endocrinology & Metabolism, vol.61, issue.3, pp.536-576, 1985. ,
DOI : 10.1210/jcem-61-3-536
Persistent Comorbidities in Cushing's Syndrome after Endocrine Cure, Front Horm Res, 2010. ,
Effect of surgical treatment on hypertension in Cushing's syndrome, American Journal of Hypertension, vol.9, issue.1, pp.77-80, 1996. ,
DOI : 10.1016/0895-7061(95)00299-5
Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure, J Clin Endocrinol Metab, vol.84, issue.8, pp.2664-72, 1999. ,
Mortality and morbidity in Cushing???s syndrome in New Zealand, Clinical Endocrinology, vol.84, issue.4, pp.436-478, 2011. ,
DOI : 10.1111/j.1365-2265.2011.04124.x
Comorbidities in Cushing's Syndrome after Endocrine Cure Advances in EndocrinologyVolume, Article ID 231432, p.231432, 2014. ,
Cushing???s Syndrome Due to Ectopic Corticotropin Secretion: Twenty Years??? Experience at the National Institutes of Health, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.8, pp.4955-62, 2005. ,
DOI : 10.1210/jc.2004-2527
Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.7, pp.2650-2655, 2006. ,
DOI : 10.1210/jc.2005-2730
Treatment of Cushing's Syndrome ,
Treatment of Adrenocorticotropin-Dependent Cushing???s Syndrome: A Consensus Statement, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.7, 2008. ,
DOI : 10.1210/jc.2007-2734
Late Recurrences of Cushing???s Disease after Initial Successful Transsphenoidal Surgery, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.2, pp.358-62, 2007. ,
DOI : 10.1210/jc.2007-2013
Term Outcome of Pituitary Irradiation after Unsuccessful Transsphenoidal Surgery in Cushing's Disease Castinetti F, Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease, N Engl J Med Eur J Endocrinol, vol.336156, issue.381, pp.172-177, 1056. ,
Radiation therapy in the multimodal treatment approach of pituitary adenoma Strahlenther Onkol HAS, Place de l'irradiation intracranniene en conditions stéreotaxique, pp.173-86, 2002. ,
Bilateral laparoscopic adrenalectomy for corticotrophin???dependent Cushing's syndrome: a review of the Mayo Clinic experience, Clinical Endocrinology, vol.116, issue.2, pp.513-522, 2008. ,
DOI : 10.1111/j.1464-410X.2004.04586.x
Corticotroph Tumor Progression after Adrenalectomy in Cushing???s Disease: A Reappraisal of Nelson???s Syndrome, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.1, pp.172-181, 2006. ,
DOI : 10.1210/jc.2006-1328
The Medical Treatment of Cushing???s Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.1, 2008. ,
DOI : 10.1210/jc.2008-1533
Cabergoline monotherapy in the long-term treatment of Cushing's disease, European Journal of Endocrinology, vol.163, issue.5, pp.709-725, 2010. ,
DOI : 10.1530/EJE-10-0382
Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients, European Journal of Endocrinology, vol.174, issue.1, pp.17-24 ,
DOI : 10.1530/EJE-15-0807
Month Phase 3 Study of Pasireotide in Cushing's Disease, N Engl J Med, vol.366, pp.914-924, 2012. ,
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study, Clinical Endocrinology, vol.362, issue.Suppl 1, p.2014 ,
DOI : 10.1111/cen.12431
Hyperglycemia induced by somatostatin analog pasireotide for the treatment of Cushing's disease Médecine des maladies MétaboliquesVolume 9, 2015. ,
SOM230: A New Somatostatin Peptidomimetic with Potent Inhibitory Effects on the Growth Hormone/Insulin-Like Growth Factor-I Axis in Rats, Primates, and Dogs, Endocrinology, vol.143, issue.10, pp.4123-4153, 2002. ,
DOI : 10.1210/en.2002-220219
Merits and pitfalls of mifepristone in Cushing's syndrome, European Journal of Endocrinology, vol.160, issue.6, pp.1003-1010, 2009. ,
DOI : 10.1530/EJE-09-0098
Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.6, pp.2039-2088 ,
DOI : 10.1210/jc.2011-3350
The use of the glucocorticoid receptor antagonist mifepristone in Cushing??s syndrome, Current Opinion in Endocrinology & Diabetes and Obesity, vol.19, issue.4, pp.295-304 ,
DOI : 10.1097/MED.0b013e32835430bf
THERAPY OF ENDOCRINE DISEASE: Steroidogenesis enzyme inhibitors in Cushing's syndrome, European Journal of Endocrinology, vol.172, issue.6, pp.263-8014, 2015. ,
DOI : 10.1530/EJE-14-1014
Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases, Treatment of Cushing's disease by O,p'DDD ,
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center, European Journal of Endocrinology, vol.167, issue.4, pp.473-81, 2012. ,
DOI : 10.1530/EJE-12-0358
Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma, Clinical Endocrinology, vol.67, issue.5, pp.585-91, 2011. ,
DOI : 10.1111/j.1365-2265.2011.04214.x
Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5??-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.1, pp.161-71, 2012. ,
DOI : 10.1210/jc.2012-2851
Mitotane Has an Estrogenic Effect on Sex Hormone-Binding Globulin and Corticosteroid-Binding Globulin in Humans, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.6, pp.2165-70, 2006. ,
DOI : 10.1210/jc.2005-2157
Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study, Clinical Endocrinology, vol.89, issue.3, pp.305-316, 2009. ,
DOI : 10.1111/j.1365-2265.2009.03631.x
The use of ketoconazole as an inhibitor of steroid production, N Engl J Med, vol.317, issue.13, pp.812-820, 1987. ,
Ketoconazole treatment in Cushing's syndrome: experience in 34 patients, Clinical Endocrinology, vol.34, issue.4, pp.347-52, 1991. ,
DOI : 10.1016/S0168-8278(86)80495-0
Ketoconazole in Cushing's Disease: Is It Worth a Try?, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.5, 2014. ,
DOI : 10.1210/jc.2013-3628
Ketoconazole inhibits corticotropic cell function in vitro ,Endocrinology, 1988. ,
Drug-drug interaction profiles of proton pump inhibitors Clin Pharmacokinet, 2010. ,
Stereoisomers of ketoconazole: preparation and biological activity, Journal of Medicinal Chemistry, vol.35, issue.15, pp.2818-2820, 1992. ,
DOI : 10.1021/jm00093a015
Treatment for Endogenous Cushing's Syndrome, 2013. ,
The medical management of Cushing's syndrome Ann N Y Acad Sci, 2002. ,
Etomidate in the Management of Hypercortisolaemia in Cushing's Syndrome, European Journal of Endocrinology, vol.167, issue.2, pp.137-180, 2012. ,
DOI : 10.1530/EJE-12-0274
Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial, Circulation, vol.124, issue.18, pp.1945-55, 2011. ,
DOI : 10.1161/CIRCULATIONAHA.111.029892
Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism, Hypertension, vol.56, issue.5, pp.831-839, 2010. ,
DOI : 10.1161/HYPERTENSIONAHA.110.157271
LCI699, a Potent 11??-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.4 ,
DOI : 10.1210/jc.2013-2117
Pharmacodynamic and Pharmacokinetic Characterization of the Aldosterone Synthase Inhibitor FAD286 in Two Rodent Models of Hyperaldosteronism: Comparison with the 11??-Hydroxylase Inhibitor Metyrapone, Journal of Pharmacology and Experimental Therapeutics, vol.334, issue.1 ,
DOI : 10.1124/jpet.110.167148
Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients, The Journal of Clinical Endocrinology & Metabolism, vol.100, issue.11, pp.4146-54 ,
DOI : 10.1210/jc.2015-2616
Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome, Clinical Endocrinology, vol.109, issue.2, pp.169-78, 1991. ,
DOI : 10.1016/S0009-9260(79)80135-X
Cross reactions elicited by serum 17-OH progesterone and 11-desoxycortisol in cortisol assays Clin Chim Acta, pp.72-76, 2009. ,
DOI : 10.1016/j.cca.2009.05.019
Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11b-hydroxylase inhibitor metyrapone, Annals of Clinical Biochemistry, pp.48-441, 2011. ,
Cortisol measurement in patients receiving metyrapone therapy, Annals of Clinical Biochemistry, vol.47, issue.6 ,
DOI : 10.1258/acb.2010.010167
An Up-To-Date Assessment of Routine Assay Performance Clin Chem, 2016. ,
Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease, New England Journal of Medicine, vol.362, issue.19 ,
DOI : 10.1056/NEJMc1000094
Cabergoline plus Lanreotide for Ectopic Cushing's Syndrome, New England Journal of Medicine, vol.352, issue.23, pp.2457-2458, 2005. ,
DOI : 10.1056/NEJM200506093522322
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome, Archives of Endocrinology and Metabolism, vol.59, issue.4, p.2015 ,
DOI : 10.1590/2359-3997000000057
Mitotane, Metyrapone, and Ketoconazole Combination Therapy as an Alternative to Rescue Adrenalectomy for Severe ACTH-Dependent Cushing's Syndrome, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.9 ,
DOI : 10.1210/jc.2011-0536
Commentaire : choix des tests diagnostiques dans l'insuffisance corticotrope, Annales d'Endocrinologie Vol, vol.59, 1998. ,
Endocrine Testing Protocols: Hypothalamic Pituitary Adrenal Axis, Inc, 2000. ,
Vers un test à la métopirone ambulatoire avec mesure du11désoxycortisolsalivaire par spectrométrie de masse Annales d'Endocrinologie ,
DOI : 10.1016/j.ando.2015.07.089
High-throughput quantitative bioanalysis by LC/MS/MS, Biomedical Chromatography, vol.71, issue.6, pp.422-431, 2000. ,
DOI : 10.1002/1099-0801(200010)14:6<422::AID-BMC25>3.0.CO;2-I